Your gift will be used to find treatments for kids with DIPG in honor of Luke Morin

Thanks to years of research funding and work in the lab, scientists have developed two innovative therapies to treat DIPG, Luke’s type of cancer:

First, they have developed CAR-T cells that safely and effectively target the DIPG tumor cells while leaving normal cells unharmed by logic-gating them to target the CD99 molecule specifically.

Second, they have developed a novel monoclonal antibody that also targets the CD99 protein. The antibody successfully crosses the blood-brain barrier and reduces the size of the tumor by suppressing CD99 activity and killing tumor cells.

These therapies have shown complete tumor clearance in testing — and they’re closer than ever to reaching children who desperately need them.

Your support truly makes a difference.